MedPath

Behandeling met radioactief jodium versus hemithyreoïdectomie, welke behandeling heeft het beste effect heeft op klachten bij patiënten met symptomatisch euthyreoot struma

Conditions
benign euthyroid goitrestruma
Registration Number
NL-OMON29617
Lead Sponsor
- AMC <br>- Flevoziekenhuis
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
70
Inclusion Criteria

Patients with symptomatic goitre

- Goitre size larger than 40 ml on one side determined on CT

Exclusion Criteria

- Goitre suspicious of malignancy on imaging

- Bethesda 5 or 6 cytology

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
reduction of symptoms 12 months after treatment measured with ThyPro Questionnaire
Secondary Outcome Measures
NameTimeMethod
- Quality of life measured by EQ-5D-5L questionnaire after 6 months and 1-5 years <br /><br>- Voice impairment after 6 months and 1-5 years as measured by the Voice Handicap<br>Index, a specific questionnaire for voice impairment detection a <br /><br>- Effect of treatment on symptoms after 6 months, 2, 3, 4 and 5 years after treatment<br>as measurd by the ThyPRO questionnairre <br /><br>- Goitre volume as measured on a CT-scan 12 months after treatment <br /><br>- Serum TSH, T4 levels, PTH (standard 2-6 weeks after treatment or if measured under<br>routine care at any time during follow-up) <br /><br>- Hypo- or hyperthyroidism <br /><br>- Peri-operative complications: vocal cords palsy <br /><br>- Complications of radioactive iodine
© Copyright 2025. All Rights Reserved by MedPath